Clinical trials
Withdrawn Phase 1/2 Breast Neoplasms trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
34 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 2 |
| 2004 | 1 |
| 2008 | 3 |
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 2 |
| 2014 | 2 |
| 2015 | 2 |
| 2016 | 2 |
| 2018 | 1 |
| 2019 | 3 |
| 2020 | 4 |
| 2021 | 2 |
| 2022 | 4 |
| 2023 | 3 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Withdrawn | 34 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| National Cancer Institute (NCI) | 2 |
| Abramson Cancer Center at Penn Medicine | 1 |
| Artiva Biotherapeutics, Inc. | 1 |
| Beth Israel Deaconess Medical Center | 1 |
| Chongqing Precision Biotech Co., Ltd | 1 |
| Context Therapeutics Inc. | 1 |
| EMD Serono Research & Development Institute, Inc. | 1 |
| Eli Avisar, MD | 1 |
| Fuda Cancer Hospital, Guangzhou | 1 |
| H. Lee Moffitt Cancer Center and Research Institute | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Breast Neoplasms | 34 |
| Neoplasm Metastasis | 4 |
| Stomach Neoplasms | 4 |
| Brain Neoplasms | 3 |
| Carcinoma, Non-Small-Cell Lung | 3 |
| Colorectal Neoplasms | 3 |
| Lung Neoplasms | 3 |
| Pancreatic Neoplasms | 3 |
| Triple Negative Breast Neoplasms | 3 |
| Carcinoma, Intraductal, Noninfiltrating | 2 |
Trials
Showing 1 to 25 of 34. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.